Safety concerns grow over Neurocrine’s Prader-Willi syndrome drug Vykat XR
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Neurocrine Biosciences’ Vykat XR has been linked to seven deaths and nearly 100 hospitalizations since its approval 18 months ago for Prader-Willi syndrome. Regulatory reports do not prove causation and involve complex cases, but some experts say the evidence indicates unacceptable harm.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu